Novo Nordisk’s newly launched oral Wegovy pill recorded 18,410 U.S. prescriptions in its first full week on the market, according to IQVIA data shared by a leading healthcare analyst. This rapid adoption places Wegovy among the fastest-tracking obesity therapies in recent years, reflecting robust demand from both prescribers and patients. Early specialty pharmacy channel fills accounted for approximately 85% of total scripts, underscoring the drug’s immediate penetration into weight-management clinics and endocrinology practices.

On January 22, 2026, Goldman Sachs maintained its Buy rating for Novo Nordisk and lifted its 12-month price target from DKK 352 to DKK 436, citing the company’s expanding obesity franchise and deepening pipeline. The firm highlighted the strategic partnership with Sesame to co-launch the Wegovy pill as a catalyst for broader market share gains. With a market capitalization near $277.1 billion and daily trading volumes exceeding 9 million shares, Novo Nordisk continues to draw strong institutional interest. Goldman analysts pointed to the combination of accelerating prescription growth, high patient retention rates in chronic indications, and potential label expansions as key drivers for further revaluation.